Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Association of genetic polymorphisms in STAT1 gene with increased risk of hepatocellular carcinoma.

Zhu ZZ, Di JZ, Gu WY, Cong WM, Gawron A, Wang Y, Zheng Q, Wang AZ, Zhu G, Zhang P, Hou L.

Oncology. 2010;78(5-6):382-8. doi: 10.1159/000320521. Epub 2010 Aug 27.

PMID:
20798561
2.

Interleukin-22 genetic polymorphisms and risk of colon cancer.

Thompson CL, Plummer SJ, Tucker TC, Casey G, Li L.

Cancer Causes Control. 2010 Aug;21(8):1165-70. doi: 10.1007/s10552-010-9542-5. Epub 2010 Mar 26.

PMID:
20339910
3.
4.

Differentiation, distribution and gammadelta T cell-driven regulation of IL-22-producing T cells in tuberculosis.

Yao S, Huang D, Chen CY, Halliday L, Zeng G, Wang RC, Chen ZW.

PLoS Pathog. 2010 Feb 26;6(2):e1000789. doi: 10.1371/journal.ppat.1000789.

5.

Interleukin-22 is a negative regulator of the allergic response.

Schnyder B, Lima C, Schnyder-Candrian S.

Cytokine. 2010 May;50(2):220-7. doi: 10.1016/j.cyto.2010.02.003. Epub 2010 Mar 2.

PMID:
20194033
6.

Natural killer receptors: the burden of a name.

Veiga-Fernandes H, Kioussis D, Coles M.

J Exp Med. 2010 Feb 15;207(2):269-72. doi: 10.1084/jem.20100105. Epub 2010 Feb 8.

7.

Renal cancer surgery in the elderly.

Roos FC, Hampel C, Thüroff JW.

Curr Opin Urol. 2009 Sep;19(5):459-64. doi: 10.1097/MOU.0b013e32832f0c7d. Review.

PMID:
19571755
8.

Epidemiology, clinical staging, and presentation of renal cell carcinoma.

Decastro GJ, McKiernan JM.

Urol Clin North Am. 2008 Nov;35(4):581-92; vi. doi: 10.1016/j.ucl.2008.07.005. Review.

PMID:
18992612
9.

Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts.

Zhang W, Chen Y, Wei H, Zheng C, Sun R, Zhang J, Tian Z.

Clin Cancer Res. 2008 Oct 15;14(20):6432-9. doi: 10.1158/1078-0432.CCR-07-4401.

10.

Tumour cell survival signalling by the ERK1/2 pathway.

Balmanno K, Cook SJ.

Cell Death Differ. 2009 Mar;16(3):368-77. doi: 10.1038/cdd.2008.148. Epub 2008 Oct 10. Review.

11.

The interleukin-22/STAT3 pathway potentiates expression of inducible nitric-oxide synthase in human colon carcinoma cells.

Ziesché E, Bachmann M, Kleinert H, Pfeilschifter J, Mühl H.

J Biol Chem. 2007 Jun 1;282(22):16006-15. Epub 2007 Apr 16.

12.

IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase.

Weber GF, Gaertner FC, Erl W, Janssen KP, Blechert B, Holzmann B, Weighardt H, Essler M.

J Immunol. 2006 Dec 1;177(11):8266-72.

13.

Expression and regulation of IL-22 in the IL-17-producing CD4+ T lymphocytes.

Chung Y, Yang X, Chang SH, Ma L, Tian Q, Dong C.

Cell Res. 2006 Nov;16(11):902-7.

14.

STAT1 as a key modulator of cell death.

Kim HS, Lee MS.

Cell Signal. 2007 Mar;19(3):454-65. Epub 2006 Sep 30. Review.

PMID:
17085014
15.

HIN-1, an inhibitor of cell growth, invasion, and AKT activation.

Krop I, Parker MT, Bloushtain-Qimron N, Porter D, Gelman R, Sasaki H, Maurer M, Terry MB, Parsons R, Polyak K.

Cancer Res. 2005 Nov 1;65(21):9659-69.

16.

Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine.

Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, Hiromura K, Ueki K, Nojima Y.

Arthritis Rheum. 2005 Apr;52(4):1037-46.

17.

IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes.

Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, Morel F.

J Immunol. 2005 Mar 15;174(6):3695-702.

18.

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB.

J Clin Oncol. 2005 Jan 1;23(1):133-41. Erratum in: J Clin Oncol. 2005 Apr 20;23(12):2877.

PMID:
15625368
19.

Targeting the mitogen-activated protein kinase cascade to treat cancer.

Sebolt-Leopold JS, Herrera R.

Nat Rev Cancer. 2004 Dec;4(12):937-47. Review.

PMID:
15573115
20.

Expression of interleukin-22 in murine carcinoma cells did not influence tumour growth in vivo but did improve survival of the inoculated hosts.

Nagakawa H, Shimozato O, Yu L, Takiguchi Y, Tatsumi K, Kuriyama T, Tagawa M.

Scand J Immunol. 2004 Nov;60(5):449-54.

Supplemental Content

Support Center